VFA
NBIX icon

Virtus Fund Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Virtus Fund Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$109K Buy
795
+27
+4% +$3.34K 0.34% 25
2024
Q3 		$88.5K Hold
768
– – 0.36% 34
2024
Q2 		$106K Buy
768
+19
+3% +$2.61K 0.42% 20
2024
Q1 		$103K Buy
749
+62
+9% +$8.47K 0.37% 30
2023
Q4 		$90.5K Buy
687
+285
+71% +$32.8K 0.56% 22
2023
Q3 		$45.2K Buy
+402
New +$42.3K 0.32% 53
2017
Q4 		$1.38M Buy
17,726
+12,419
+234% +$847K 0.01% 268
2017
Q3 		$325K Sell
5,307
-330
-6% -$17.4K ﹤0.01% 335
2017
Q2 		$263K Sell
5,637
-168
-3% -$8.15K ﹤0.01% 377
2017
Q1 		$251K Sell
5,805
-3,106
-35% -$133K ﹤0.01% 394
2016
Q4 		$345K Sell
8,911
-3,059
-26% -$138K ﹤0.01% 375
2016
Q3 		$606K Hold
11,970
– – 0.01% 308
2016
Q2 		$542K Hold
11,970
– – ﹤0.01% 328
2016
Q1 		$473K Sell
11,970
-2,540
-18% -$101K ﹤0.01% 349
2015
Q4 		$821K Sell
14,510
-152
-1% -$7.72K 0.01% 299
2015
Q3 		$583K Sell
14,662
-43,896
-75% -$2.12M 0.01% 332
2015
Q2 		$2.8M Sell
58,558
-816
-1% -$34.6K 0.02% 278
2015
Q1 		$2.36M Sell
59,374
-5,524
-9% -$198K 0.02% 308
2014
Q4 		$1.45M Buy
64,898
+314
+0.5% +$5.95K 0.01% 357
2014
Q3 		$1.01M Sell
64,584
-6,020
-9% -$90K 0.01% 396
2014
Q2 		$1.05M Buy
+70,604
New +$996K 0.01% 445

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtus Fund Advisers's NBIX Position: Q4 2024 in Review

Virtus Fund Advisers increased its Neurocrine Biosciences (NBIX) stake by 3.5% in Q4 2024, buying an estimated $3.34K and bringing the position to 795 shares worth $109K. The position accounts for 0.34% of the portfolio, ranked #25.

Virtus Fund Advisers first reported a position in NBIX in Q2 2014 and has held it in 21 quarters since. The position peaked at $2.8M in Q2 2015. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Virtus Fund Advisers held 795 shares of Neurocrine Biosciences worth $109K as of Q4 2024.
  • Virtus Fund Advisers bought 27 Neurocrine Biosciences shares in Q4 2024, an estimated $3.34K.
  • Neurocrine Biosciences made up 0.34% of Virtus Fund Advisers's portfolio in Q4 2024, its #25 holding.
  • Virtus Fund Advisers first reported a position in Neurocrine Biosciences in Q2 2014 and has held it in 21 quarters since.
  • Virtus Fund Advisers's Neurocrine Biosciences position peaked at $2.8M in Q2 2015.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Virtus Fund Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.